First in Human Trial of TAS266 in Patients With Advanced Solid Tumors

Inclusion Criteria: * Confirmed diagnosis of solid tumors * 18 years or older * ECOG performance status of 0, 1 or 2 * Adequate bone marrow, hepatic and renal function * Obtained written informed consent Exclusion Criteria: * Patients with primary CNS tumor or CNS tumor involvement. However patients with CNS metastases may be allowed if certain conditions are met. * Major surgery within 4 weeks before study treatment * Prior anaphylactic or other severe infusion reactions to human immunoglobulin or antibody formulations * Impaired cardiac functions * Previous hepatitis viral infection such as hepatitis B or hepatitis C * Diagnosis of HIV infection * Pregnant or nursing (lactating) women Other protocol-defined inclusion/exclusion criteria may apply